{{Drugbox
| IUPAC_name = ''N'',''N''-diethyl-''N''-((2-(1-pentyl-1''H''-indol-3-yl)thiazol-4-yl)methyl)ethanamine
| image = PTI-1_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1400742-46-2
| ATC_prefix =  
| ATC_suffix =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FSE9R26430
| PubChem =  
|  ChemSpiderID = 32055537
| smiles            = CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl
| StdInChI          = 1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H
| StdInChIKey       = NPYOTZAJIONLKZ-UHFFFAOYSA-N

<!--Chemical data-->
| C=21 | H=29 | N=3 | S=1
| molecular_weight = 355.54 g/mol
}}

'''PTI-1''' is an [[indole]]-based [[synthetic cannabinoid]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/9001948 | title=PTI-1 | publisher=Cayman Chemical | accessdate=8 July 2015}}</ref> It is one of few [[synthetic cannabinoid|synthetic cannabinoids]] containing a [[thiazole]] group and is closely related to [[PTI-2]]. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by [[Organon International|Organon]] and subsequently further researched by [[Merck & Co.|Merck]].<ref>[http://www.google.com/patents/US7700634 Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004]</ref><ref>[http://www.google.com/patents/US7763732 Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005]</ref><ref>[https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008101995 Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007]</ref><ref>Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. ''Bioorganic and Medicinal Chemistry Letters'' 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082</ref>

==See also==

* [[JWH-018]]
* [[LBP-1 (drug)]]
* [[PTI-2]]

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Indoles]]
[[Category:Thiazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]

{{cannabinoid-stub}}